Sociodemographic disparities in access to addiction treatment among a cohort of Vancouver injection drug users.

scientific article published in January 2005

Sociodemographic disparities in access to addiction treatment among a cohort of Vancouver injection drug users. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1081/JA-200042287
P8608Fatcat IDrelease_uz7aekec4fduho6tii3zuzyvve
P698PubMed publication ID16040375
P5875ResearchGate publication ID7705886

P50authorJulio MontanerQ1712378
Anita PalepuQ42399208
Thomas KerrQ85344273
Evan WoodQ85344858
Robert S HoggQ37837778
Martin T. SchechterQ40448698
David C. MarshQ42393440
P2093author name stringKathy Li
P2860cites workIntensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemicQ42595766
The potential public health and community impacts of safer injecting facilities: evidence from a cohort of injection drug usersQ42692167
Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programmeQ43937466
Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug usersQ44116660
Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trialQ44460929
Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapyQ45710860
Drug treatment on demand--not.Q45993928
Cost-benefit and cost-effectiveness analysis of drug abuse treatment services.Q51991546
The role of epidemiology in needle exchange programs.Q52925559
Science and health policy: can they cohabit or should they divorce?Q53513004
Needle exchange, pragmatism, and moralism.Q53513008
Epidemiology and the politics of needle exchange.Q53513014
Needle exchange and difficulty with needle access during an ongoing HIV epidemicQ57259768
Rationale for evaluating North America's first medically supervised safer-injecting facilityQ57671841
HIV incidence among injecting drug users in New York City syringe-exchange programmesQ30233828
Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspectiveQ30670433
Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak.Q30730194
A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependenceQ33923812
Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up studyQ34101461
Needle exchange is not enough: lessons from the Vancouver injecting drug use studyQ34432600
The social determinants of emergency department and hospital use by injection drug users in CanadaQ36274713
Social costs of untreated opioid dependenceQ36274931
Risk-taking behaviors among injecting drug users who obtain syringes from pharmacies, fixed sites, and mobile van needle exchangesQ36275042
Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trialQ41724594
P433issue8
P921main subjectsociodemographyQ3487479
P304page(s)1153-1167
P577publication date2005-01-01
P1433published inSubstance Use and MisuseQ15753729
P1476titleSociodemographic disparities in access to addiction treatment among a cohort of Vancouver injection drug users.
P478volume40

Reverse relations

cites work (P2860)
Q42695632'Because I've been extremely careful': HIV seroconversion, responsibility, citizenship and the neo-liberal drug-using subject
Q39947017A peer-led mobile outreach program and increased utilization of detoxification and residential drug treatment among female sex workers who use drugs in a Canadian setting
Q39858715A primary care/multidisciplinary harm reduction clinic including opiate bridging
Q37154026Access to drug and alcohol treatment among a cohort of street-involved youth.
Q35966106An Engineered Endomorphin-2 Gene for Morphine Withdrawal Syndrome
Q36928874Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?
Q59238934Complex vulnerabilities as barriers to treatment for illicit drug users with high prevalence mental health co-morbidities
Q36616450Factors associated with inability to access addiction treatment among people who inject drugs in Vancouver, Canada
Q36316034Factors that help injecting drug users to access and benefit from services: A qualitative study
Q39959718Harm reduction in hospitals: is it time?
Q35679629Inability to access addiction treatment among street-involved youth in a Canadian setting
Q35127554Inability to access addiction treatment and risk of HIV infection among injection drug users recruited from a supervised injection facility.
Q41502073Injection drug use cessation and use of North America's first medically supervised safer injecting facility
Q34023279Methadone use among HIV-positive injection drug users in a Canadian setting
Q37091192NAOMI: The trials and tribulations of implementing a heroin assisted treatment study in North America.
Q47625227Need for equity in treatment of substance use among Indigenous people in Canada
Q48013189Perceived unmet need and barriers to care amongst street-involved people who use illicit drugs.
Q24673390Summary of findings from the evaluation of a pilot medically supervised safer injecting facility
Q36985312The North American Opiate Medication Initiative (NAOMI): profile of participants in North America's first trial of heroin-assisted treatment.
Q33874564The impact of engagement in street-based income generation activities on stimulant drug use cessation among people who inject drugs
Q34764625The role of safer injection facilities in the response to HIV/AIDS among injection drug users.
Q37329865Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note